Medically reviewed by Lindsay Cook, PharmD Key Takeaways HER2-positive breast cancers have more HER2 receptors and can grow and spread faster than HER2-negative cancers.HER2 status should be tested ...

For patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive, high-risk ...

The investigational PAM inhibitor extends progression-free survival from 5 to 7 months in patients with advanced, PIK3CA wild ...

Sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival compared to chemotherapy in HR-positive, ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

A newly developed antibody which restricts the growth of treatment-resistant breast cancers offers new hope for patients.

Sacituzumab govitecan significantly improved survival outcomes for previously untreated, PD-L1-negative metastatic ...

Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 ...

Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily chemotherapy for now.

Shortly after her 50th birthday, Shewanna Strickland's routine mammogram revealed a troubling spot on her breast.

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...